Partnering

In addition to advancing our own clinical pipeline in oncology, Cristal Therapeutics has forged a number of strategic partnerships with pharmaceutical and biotechnology companies to co-develop therapeutic nanomedicines and assess their applicability across a number of therapeutic areas.

CPC 634

We plan to partner / out-license CPC634, our lead product candidates after Phase 2 studies to pharmaceutical companies with late stage development and commercialisation capabilities in attractive geographic territories.

Our CriPec^® technology platform

Available for the co-development of additional partner companies’ therapeutic molecules in the area of (immune-) oncology as well as across a range of disease indications that includes, but is not limited to, chronic inflammation. The CriPec^® platform has the potential to create passive or cellular targeted nanomedicines that incorporate a single type of therapeutic molecules or a combination thereby providing potentially superior therapeutic outcomes.

Inflammation program

In addition CPC289, the therapeutic asset from our inflammation program is ready for pre-clinical development and is available for out-licensing.

Our CliCr^® technology platform: ready to connect

Suitable for generating superior and novel conjugate products including bioconjugate-based therapeutics, nanomedicines, biomaterials and diagnostics, our proprietary click chemistry platform is available for testing through joint proof of concept studies with further development under a license.

Partnering opportunities

To find out more about partnering opportunities,
email: partnering@cristaltherapeutics.com
or use the form below.